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JAK2 V617F‐mutated	cells.	HEL	cell	 line	and	cells	 from	patients	JAK2 V617F	mutated	
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1  | INTRODUC TION
Myeloproliferative	 neoplasms	 (MPNs)	 are	 clonal	 hematopoietic	
stem	cell	disorders	characterized	by	an	uncontrolled	proliferation	of	
one	or	more	elements	of	the	myeloid	lineage.1	In	addition	to	chronic	











induce	 the	 expression	 of	 target	 genes,	 such	 as	 PIM‐1,	 PIM‐2	 and	
PIM‐3,	serine/threonine	kinases	that	promote	cells	survival,	prolif‐
eration	 and	 therapy	 resistance.3 JAK2	mutations	 directly	 activate	
JAK/STAT	signalling	and	make	myeloproliferation	cytokine	indepen‐
dent	or	hypersensitive.	JAK/STAT	deregulation	is	critical	for	MPNs	




vival	 and	 it	may	 form	different	 proteins	 complexes:	mTORC1	 and	
mTORC2.	mTORC1	is	composed	of	mTOR,	Raptor,	GβL	and	DEPTOR	
and	it	is	regulated	by	AKT.	In	normal	cells,	mTORC1	is	essential	for	
erythroid	 and	megakaryocytic	 differentiation	 through	 the	 activa‐
tion	of	 downstream	effectors	 including	4eBP1	 and	p70s6K.6	This	
pathway	 has	 been	 found	 deregulated	 particularly	 in	 megakaryo‐
cytes	of	MPNs	patients.7	The	deregulation	of	JAK/STAT	and	mTOR	
pathways	 induces	 an	 inflammatory	 state	 with	 aberrant	 cytokine	
expression.8	Given	 the	heterogeneous	clinical	needs	of	MPNs	pa‐
tients,	 determination	 of	 a	 standard	 therapeutic	 protocol	 is	 often	






inflammatory,	 anti‐microbial,	 anti‐oxidative	 and	 anti‐proliferative	
activities.10,11	 Extensive	 preclinical	 trials	 have	 indicated	 curcumin	
therapeutic	 potential	 against	 a	 wide	 range	 of	 human	 diseases.12 
Previous	 studies	 showed	 that	 curcumin	 can	 suppress	 JAK2/STAT	
signalling	 pathways	 in	 different	 type	 of	 cancer	 and	 injuries.13,14 
Chen	 et	 al	 demonstrated	 that	 curcumin	 increased	 the	 transcript	





















patients	were	 JAK2 V617F	mutated.	 The	 study	was	 approved	 by	 the	
ethic	committee	on	16	December	2015	(number	of	approval	212/2015).
2.3 | Cells treatment
HEL	 cells	 were	 incubated	 with	 different	 concentrations	 (10,	 15,	
20,	 30	µmol/L)	 of	 curcumin	 (stock	 solution	 50	mmol/L	 in	DMSO,	









V	 positive.	 HEL	 cells	 were	 treated	 with	 increasing	 concentration	
of	curcumin	 for	24	and	48	hours.	After	 incubation,	cells	were	har‐
vested,	 resuspended	 in	 Flow	Cytometry	 Staining	 Buffer	 (#FC001,	
R&D	Systems)	and	labelled	with	1	μg/μL	propidium	iodide	(PI).	Live	
cells	(PI	negative	fraction)	were	counted	by	FACS.
2.5 | Protein extraction and immunoblotting




and	 phosphatase	 inhibitors	 cocktail	 [Sigma‐Aldrich])	 and	 cell	 debris	
were	 removed	 by	 centrifugation	 at	 14	000g	 at	 4°C	 for	 15	minutes.	
Protein	concentration	was	determined	by	Bio‐Rad	Protein	Assay	(Bio‐









bands	 were	 visualized	 by	 Clarity	 Western	 ECL	 Substrate	 (Bio‐Rad).	
Quantification	was	performed	using	Image	Lab	program	(Bio‐Rad).
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2.6 | Co‐immunoprecipitation
HEL	 cells	 (15	 million	 for	 each	 condition)	 were	 rinsed	 with	 cold	
PBS	and	lysed	on	ice‐cold	CHAPS	buffer	lacking	NaCl	(40	mmol/L	
HEPES	[pH	7.4],	0.3%	CHAPS,	protease	and	phosphatase	inhibitors)	
to	 isolate	mTORC1	 complex.17	Cell	 debris	was	 removed	 from	 the	
lysates	by	centrifugation	at	16	200g	for	15	minutes	at	4°C,	followed	
by	 pre‐cleaning	 with	 Protein	 A/G	 PLUS‐Agarose	 (sc‐2003,	 Santa	
Cruz	Biotechnology).	mTOR	antibody	(Table	1)	for	co‐immunopre‐
cipitation	was	added	to	the	lysate	(1	mg/mL)	and	incubated	ON	at	
4°C.	 Protein	 A/G	 (20	μL)	 were	 added	 to	 the	 antibody	 and	 lysate	
mixture	and	incubated	1	hour	at	4°C	in	a	rotator.	The	mock	control	
(beads	 and	whole	 cell	 lysates	without	 adding	 antibody)	was	used	
to	exclude	the	false	 interaction	of	 lysate	proteins	with	the	beads.	
Immunoprecipitates	 and	 mock	 controls	 were	 washed	 once	 with	
CHAPS	 buffer	 lacking	 NaCl	 and	 three	 times	 with	 CHAPS	 buffer	
containing	150	mmol/L	NaCl.	Samples	were	eluted	 in	5×	Laemmli	
buffer	 at	 95°C	 for	 10	minutes	 and	 resolved	 on	 6%	 SDS‐PAGE	 as	
described	above.	mTOR‐Raptor	complex	was	evaluated	using	mTOR	
and	Raptor	antibodies	(Table	1)	as	previously	described.
2.7 | RNA extraction and qRT‐PCR analysis
Total	 RNA	 was	 extracted	 using	 TRIzol	 Reagent	 (Ambion,	 Thermo	
Fisher	 Scientific),	 following	 the	 manufacturer's	 instructions.	 1	µg	
on	total	RNA	was	used	as	a	template	for	the	reverse	transcription	
reaction.	 Expression	 levels	 of	 PIM1	 (Hs_00171473_m1),	 PIM2	
(Hs_00179139_m1),	PIM3	(Hs00420511_g1),	CD177	(Hs00360669_
m1),	 Socs‐1	 (Hs00705164_s1)	 and	 Socs‐3	 (Hs00269575_s1)	 were	
evaluated	with	TaqMan	technology	(TaqMan	Universal	Master	Mix,	
Thermo	Fisher	Scientific)	with	C1000	Thermal	Cycler	CFX96	Real‐




Statistical	 analyses	 were	 performed	 using	 the	 two‐tailed	 Mann‐




3.1 | Curcumin induces apoptosis and inhibits 




and	 immunoblotting.	 The	 viability	 of	 the	HEL	 cells	 exposed	 to	 cur‐
cumin	was	significantly	 lower	compared	 to	control	cells	even	at	 low	
TA B L E  1  List	of	primary	antibodies
Antibody Catalog n° Company Species
JAK2	(C‐14) sc‐34479 Santa	Cruz	Biotechnology Goat
p‐JAK2	(Tyr221) sc‐101718 Santa	Cruz	Biotechnology Rabbit
Stat3	(F‐2) sc‐8019 Santa	Cruz	Biotechnology Mouse
Stat5	(A‐9) sc‐74442 Santa	Cruz	Biotechnology Mouse
p‐Akt1/2/3	(Thr308)‐R sc‐16646‐R Santa	Cruz	Biotechnology Rabbit
Raptor	(10E10) sc‐81537 Santa	Cruz	Biotechnology Mouse
GAPDH	(A‐3) Sc‐137179 Santa	Cruz	Biotechnology Mouse
p70	S6	kinase	α	(H‐9) sc‐8418 Santa	Cruz	Biotechnology Mouse
SOCS‐1	(H93) sc‐9021 Santa	Cruz	Biotechnology Rabbit
SOCS‐3	(SO1) sc‐51699 Santa	Cruz	Biotechnology Mouse
Phospho‐	p70	S6	kinase	(Thr389) 9208 Cell	Signaling	Technology Rabbit
Phospho‐Raptor	(Ser792) 2083 Cell	Signaling	Technology Rabbit
PDK1 3062 Cell	Signaling	Technology Rabbit
Phospho‐PDK1	(Tyr373/376) 3065 Cell	Signaling	Technology Rabbit
Phospho‐STAT5	(Tyr694)	(D47E7) 4322 Cell	Signaling	Technology Rabbit
Phospho‐STAT3	Tyr	705	(D3A7) 9145 Cell	Signaling	Technology Rabbit
Akt	(pan)	(C67E7) 4691 Cell	Signaling	Technology Rabbit
4E‐BP1 9452 Cell	Signaling	Technology Rabbit
p4E‐BP1 9451 Cell	Signaling	Technology Rabbit
Cleaved	Caspase‐3 9661 Cell	Signaling	Technology Rabbit
mTOR ab2732 Abcam Rabbit
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concentrations.	 In	 addition,	 the	 curcumin	 growth	 inhibitory	 effect	
was	dose	and	 time‐dependent,	 reaching	 the	maximum	effect	 at	 the	
dose	of	20	µmol/L	for	48	hours,	by	reducing	the	proliferation	of	93%	
(Figure	1A).	The	 results	obtained	evaluating	apoptosis	with	Annexin	




















30	µmol/L	 showed	a	 reduction	of	 JAK2	phosphorylation	of	 about	
30%,	the	functionality	of	JAK2	to	phosphorylate	 its	effectors	was	
strong	 compromised.	 The	 phosphorylation	 of	 STAT5	 and	 STAT3,	
the	 direct	 effectors	 of	 JAK2,	was	 strongly	 inhibited	 by	 curcumin.	
Indeed,	we	observed	 that	phosphorylation	of	 STAT5	was	60%	 re‐
duced,	while	STAT3	was	extremely	sensitive	to	curcumin‐mediated	




up‐regulated	 after	 curcumin	 treatment.	 Indeed,	 their	 expression	





times	even	at	15	µmol/L	of	 curcumin	 (P	<	0,01)	 (Figure	2B).	These	
results	were	further	corroborated	by	measuring	the	transcriptional	
activity	of	 JAK	downstream	effectors	STATs	on	mRNA	expression	





3.3 | Curcumin modulates mTORC1 signalling by the 
inhibition of PDK and AKT in HEL cells line
To	 investigate	 how	 curcumin	 affects	mTORC1	 pathway,	HEL	 cells	
were	treated	with	various	concentrations	of	curcumin	(0‐30	µmol/L)	
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for	24	hours	and	analysed	by	immunoblotting.	Our	results	indicated	
that	 curcumin	 affects	 the	 principal	 modulator	 of	 mTORC1:	 AKT.	
Phosphorylation	of	AKT	in	Thr308	was	reduced	in	dose‐dependent	
manner	 and	 its	principal	 activator	PDK	was	 inhibited	by	 low	dose	
curcumin	and	 it	appeared	unphosphorylated	at	the	maximum	con‐




cipal	 downstream	 effectors	 of	mTORC1.	 In	 particular,	we	 showed	
the	 dephosphorylation	 of	 p70s6K,	 which	 is	 usually	 activated	 by	
phosphorylation,	 and	 the	 increase	 of	 unphosphorylated	 form	 of	
4eBP1,	usually	inhibited	through	mTORC1	phosphorylation.
3.4 | Curcumin induces apoptosis and reduces 





est	 concentration	 utilized	 in	 vitro	 (30	µmol/L)	 for	 20	hours	 and	 the	


























P	<	0.0001)	 (Figure	 4A).	 Interestingly,	 except	 for	 PIM2	 (P	=	0.025)	
(Figure	4A),	the	mRNA	expression	of	PIM	family	members	and	CD177	








The	majority	of	Philadelphia	negative	MPNs	 shows	 the	 single	base	
JAK2 V617F	mutation	that	results	 in	a	constitutive	activation	of	the	










and	anti‐carcinogenic	effects	by	 targeting	 JAK2	 signalling	 in	differ‐
ent	type	of	neoplasms	and	injuries,14,20	but	the	effects	of	this	phyto‐
chemical	on	JAK2‐mutated	cells	have	been	poorly	studied	until	now.
In	 this	work,	we	 investigated,	 at	 both	RNA	 and	 protein	 levels,	
the	 effects	 of	 curcumin	 on	 JAK2/STAT	 pathway,	 known	 to	 be	 al‐
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a	dose	and	time‐dependent	manner	 in	HEL	cells.	Furthermore,	we	
found	that	curcumin	markedly	reduced	JAK2	phosphorylation	and,	
consequently,	 the	 activation	 of	 its	 downstream	 effectors	 STAT3	
and	 STAT5	 in	HEL	 cells,	 according	 to	 the	 results	 obtained	by	Zhu	
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